Table 1.
Baseline characteristics of incarcerated HCV patients
| Variable | Total (n=1,001) | Restricted DAA access (n=320) | Unrestricted DAA access (n=681) | P-value* |
|---|---|---|---|---|
| Age (years) | 50.3±9.6 | 52.4±7.9 | 49.3±10.2 | <0.001 |
| Gender | 928 (92.7) | 303 (94.7) | 625 (91.8) | 0.061 |
| HCV RNA (log IU/mL) | 5.9±0.9 | 5.9±0.9 | 6.0±0.9 | 0.116 |
| Genotype | 0.370 | |||
| 1 | 241 (24.1) | 72 (22.5) | 169 (24.8) | |
| 2 | 14 (1.4) | 5 (1.6) | 9 (1.3) | |
| 3 | 712 (71.1) | 237 (74.1) | 475 (69.8) | |
| 4 | 4 (0.4) | 0 | 4 (0.6) | |
| 6 | 2 (0.2) | 0 | 2 (0.3) | |
| Indeterminate | 28 (2.8) | 6 (1.9) | 22 (3.2) | |
| Fibrosis stage | <0.001 | |||
| F0/F1 | 231 (23.1) | 11 (3.4) | 220 (32.3) | |
| F2 | 94 (9.4) | 12 (3.8) | 82 (12.0) | |
| F3 | 185 (18.5) | 81 (25.3) | 104 (15.3) | |
| F4 | 383 (38.2) | 209 (65.3) | 174 (25.6) | |
| Not available | 108 (10.8) | 7 (2.2) | 101 (14.8) | |
| Cirrhosis-related complications | ||||
| Ascites | 22 (2.2) | 12 (3.8) | 10 (1.5) | 0.022 |
| Esophageal varices | 66 (6.6) | 37 (11.6) | 29 (4.3) | <0.001 |
| Hepatic encephalopathy | 9 (0.9) | 4 (1.3) | 5 (0.7) | 0.316 |
| HCC | 14 (1.4) | 4 (1.3) | 10 (1.5) | 0.520 |
| Co-infection | ||||
| HIV | 8 (0.8) | 4 (1.3) | 4 (0.6) | 0.229 |
| HBV | 11 (1.1) | 4 (1.3) | 7 (1.0) | 0.486 |
| Laboratory results | ||||
| Albumin (g/L) | 44±4 | 43±5 | 45±4 | <0.001 |
| Bilirubin (mmol/L) | 13.8±8.8 | 15.7±8.2 | 12.9±9.0 | <0.001 |
| Platelet (103/uL) | 198±70 | 168±73 | 212±64 | <0.001 |
| Sodium (mmol/L) | 140.2±2.6 | 139.6±2.6 | 140±2.6 | <0.001 |
| Creatinine (mmol/L) | 85.1±28.2 | 86.5±39.1 | 84.5±21.2 | 0.293 |
| PT (seconds) | 10.5±1.1 | 10.8±1.4 | 10.4±0.8 | <0.001 |
| DAA | 782 (78.1) | 135 (42.2) | 647 (95.0) | <0.001 |
| Complete treatment | 974 (97.3) | 298 (93.1) | 676 (99.3) | <0.001 |
| SVR; ITT | ||||
| Not detected | 937 (93.6) | 268 (83.8) | 669 (98.2) | |
| Detected | 29 (2.9) | 23 (7.2) | 6 (0.9) | |
| Defaulted | 35 (3.5) | 29 (9.1) | 6 (0.9) | |
| PP | 937 (97.0) | 268 (92.1) | 280 (99.1) | 0.003 |
Values are presented as mean±standard deviation or number (%).
HCV, hepatitis C virus; DAA, direct-acting antivirals; HCC, hepatocellular carcinoma; HIV, human immunodeficiency virus; HBV, hepatitis B virus; PT, prothrombin time; SVR, sustained-virological response; ITT, intention-to-treat.
*
P -value comparison between restricted and unrestricted DAA access era.